Human Anti-IAV HA Recombinant Antibody (clone FluA-20) (CAT#: PABJ-0204)

Figure 1 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in SDS-PAGE

SDS-PAGE analysis of PABJ-0204 in non-reduced and reduced conditions. Gel stained for 30 minutes with Coomassie Blue. As a result of different β-mercaptoethanol-reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively

Figure 2 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in SEC-HPLC

The purity of PABJ-0204 was greater than 95% as determined by SEC-HPLC.

Figure 3 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in ELISA

ELISA analysis of PABJ-0204 was performed by coating with Influenza A H1N1 (A/Brevig Mission/1/1918) Hemagglutinin Protein (HA1 Subunit) (His Tag).

Antigen: 2 μg/ml, 100 μL/well
The secondary antibody: HRP-Anti-Human IgG (H+L)

Figure 4 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in ELISA

ELISA analysis of PABJ-0204 was performed by coating with Influenza A H3N2 (A/Perth/16/2009) Hemagglutinin / HA Protein (His Tag). Then blocked with BSA and incubated with PABJ-0204. The HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 5 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in ELISA

ELISA analysis of PABJ-0204 was performed by coating with Influenza A H3N2 (A/Victoria/210/2009) Hemagglutinin / HA Protein (His Tag). Then blocked with BSA and incubated with PABJ-0204. The HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 6 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in ELISA

ELISA analysis of PABJ-0204 was performed by coating with Influenza A H2N2 (A/Japan/305/1957) Hemagglutinin / HA Protein (His Tag). Then blocked with BSA and incubated with PABJ-0204. The HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 7 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in ELISA

ELISA analysis of PABJ-0204 was performed by coating with Influenza A [A/Hong Kong/483/97 (H5N1)] Hemagglutinin (HA) Protein (His Tag). Then blocked with BSA and incubated with PABJ-0204. The HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 8 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in WB

Western blot analysis of PABJ-0204 was performed with Influenza A H1N1 (A/Brevig Mission/1/1918) Hemagglutinin Protein (HA1 Subunit) (His Tag).

PABJ-0204 incubation concentration: 2 ng/μL.
The secondary antibody: HRP-Anti-Human IgG (H+L)
Lane1: Reducing antigen (0.1 μg)
Lane2: Reducing antigen (0.3 μg)
Lane3: Reducing antigen (0.6 μg)

Figure 9 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in WB

Western blot analysis of PABJ-0204 was performed with Influenza A H3N2 (A/Perth/16/2009) Hemagglutinin / HA Protein (His Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with PABJ-0204 and HRP goat anti-Human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.

Lane 1: Reduced antigen (0.3 μg)
Lane 2: Reduced antigen (0.6 μg)

Figure 10 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in WB

Western blot analysis of PABJ-0204 was performed with Influenza A H3N2 (A/Victoria/210/2009) Hemagglutinin / HA Protein (His Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with PABJ-0204 and HRP goat anti-Human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.

Lane 1: Reduced antigen (0.3 μg)
Lane 2: Reduced antigen (0.6 μg)

Figure 11 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in WB

Western blot analysis of PABJ-0204 was performed with Influenza A H2N2 (A/Japan/305/1957) Hemagglutinin / HA Protein (His Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with PABJ-0204 and HRP goat anti-Human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.

Lane 1: Reduced antigen (0.3 μg)
Lane 2: Reduced antigen (0.6 μg)

Figure 12 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in WB

Western blot analysis of PABJ-0204 was performed with Influenza A [A/Hong Kong/483/97 (H5N1)] Hemagglutinin (HA) Protein (His Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with PABJ-0204 and HRP goat anti-Human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.

Lane 1: Reduced antigen (0.3 μg)
Lane 2: Reduced antigen (0.6 μg)

Figure 13 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in DB

Dot Blot analysis of PABJ-0204 was performed by coating with Influenza A H1N1 (A/Brevig Mission/1/1918) Hemagglutinin Protein (HA1 Subunit) (His Tag).

PABJ-0204 incubation concentration: 2 ng/μL.
The secondary antibody: HRP-Anti-Human IgG (H+L)

Figure 14 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in DB

Dot Blot analysis of PABJ-0204 was performed by coating with Influenza A H3N2 (A/Perth/16/2009) Hemagglutinin / HA Protein (His Tag).

PABJ-0204 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000)

Figure 15 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in DB

Dot Blot analysis of PABJ-0204 was performed by coating with Influenza A H3N2 (A/Victoria/210/2009) Hemagglutinin / HA Protein (His Tag).

PABJ-0204 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000)

Figure 16 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in DB

Dot Blot analysis of PABJ-0204 was performed by coating with Influenza A H2N2 (A/Japan/305/1957) Hemagglutinin / HA Protein (His Tag).

PABJ-0204 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000)

Figure 17 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in DB

Dot Blot analysis of PABJ-0204 was performed by coating with Influenza A [A/Hong Kong/483/97 (H5N1)] Hemagglutinin (HA) Protein (His tag).

PABJ-0204 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000)